Anido Armando's Form 4 filing
Zynerba Pharmaceuticals, Inc. (ZYNE) · filed Sep 14, 2023
- Accession no.
- 0001062993-23-018018
- Filed
- Sep 14, 2023
- Trade date
- Sep 12-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $23.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anido ArmandoCIK 0001219866 | Director, Officer (Chairman & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Common Stock | AGrant or awardAcquired | +64,747 | –F1 | – | 954,552 | Direct | |
| Sep 13, 2023 | Common Stock | SSaleDisposed | −17,830 | $1.33 | −$23,713.9 | 936,722 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year.
Referenced by the price of 1 transaction in Table I.